Zenas Biopharma (ZBIO) Stock Price

Zenas Biopharma Price

NYSE·CLOSED
29.51USD+0.31 (+1.06 %)
Market closed

Revenue at Zenas Biopharma has contracted by 55.3% per year over the past 2 years to 10.00 M USD. Zenas Biopharma's net margin stands at -3,777.4%, down from -74.2% several years earlier. Analysts set a median price target of 45.39 USD, implying 53.8% above the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 283% above its 52-week low.

Zenas Biopharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Zenas Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zenas Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zenas Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Zenas Biopharma Stock Price History
DateZenas Biopharma Price
8/14/202629.51 USD
8/13/202629.20 USD
8/12/202631.54 USD
8/10/202631.78 USD
8/7/202632.43 USD
8/6/202632.17 USD
8/5/202631.46 USD
8/4/202631.45 USD
8/3/202631.13 USD
7/31/202631.44 USD
7/30/202632.27 USD
7/29/202630.99 USD
7/27/202632.51 USD
7/23/202630.99 USD
7/22/202631.49 USD
7/21/202632.36 USD
7/20/202630.70 USD
7/17/202629.53 USD
7/16/202628.24 USD
7/15/202629.41 USD
7/14/202628.78 USD
7/13/202628.10 USD
7/10/202628.74 USD
7/9/202629.43 USD
7/8/202628.32 USD
7/7/202627.68 USD
7/6/202627.25 USD
7/2/202627.23 USD
7/1/202628.00 USD
6/30/202625.38 USD
6/29/202625.22 USD
6/26/202625.87 USD
6/25/202624.67 USD
6/24/202621.80 USD
6/23/202620.20 USD
6/22/202620.63 USD
6/18/202619.25 USD
6/17/202618.64 USD
6/16/202618.24 USD
6/15/202619.51 USD
6/12/202619.83 USD
6/11/202617.79 USD
6/10/202618.77 USD
6/9/202618.42 USD
6/8/202617.61 USD
6/5/202618.49 USD
6/4/202618.46 USD
6/3/202617.38 USD
6/2/202617.21 USD
6/1/202618.07 USD
5/29/202618.61 USD
5/28/202618.67 USD
5/27/202618.45 USD
5/26/202618.94 USD
5/22/202619.30 USD
5/21/202619.82 USD
5/20/202618.79 USD
5/19/202617.84 USD
5/18/202616.91 USD
5/15/202618.34 USD
5/14/202618.90 USD
5/13/202619.93 USD
5/12/202619.16 USD
5/11/202620.40 USD
5/8/202619.64 USD
5/7/202619.27 USD
5/6/202620.83 USD
5/5/202620.76 USD
5/4/202621.56 USD
5/1/202619.36 USD
4/30/202619.32 USD
4/29/202617.55 USD
4/28/202618.01 USD
4/27/202618.59 USD
4/24/202618.19 USD
4/23/202618.49 USD
4/22/202620.07 USD
4/21/202620.44 USD
4/20/202620.90 USD
4/17/202621.82 USD
4/16/202621.76 USD
4/15/202621.05 USD
4/14/202621.34 USD
4/13/202621.04 USD
4/10/202620.44 USD
4/9/202621.28 USD
4/8/202620.86 USD
4/7/202622.48 USD
4/6/202622.26 USD
4/2/202621.46 USD
4/1/202620.36 USD
3/31/202619.55 USD
3/30/202618.23 USD
3/27/202618.21 USD
3/26/202622.16 USD
3/25/202622.19 USD
3/24/202621.06 USD
3/23/202620.63 USD
3/20/202622.30 USD
3/19/202623.37 USD
3/18/202623.03 USD
3/17/202623.48 USD
3/16/202623.23 USD
3/13/202624.04 USD
3/12/202624.50 USD
3/11/202625.34 USD
3/10/202625.92 USD
3/9/202626.14 USD
3/6/202625.28 USD
3/5/202625.26 USD
3/4/202625.82 USD
3/3/202625.18 USD
3/2/202625.56 USD
2/27/202626.35 USD
2/26/202626.36 USD
2/25/202626.03 USD
2/24/202626.07 USD
2/23/202626.14 USD
2/20/202625.88 USD
2/19/202627.02 USD
2/18/202626.68 USD
2/17/202626.77 USD
2/13/202626.40 USD
2/12/202626.11 USD
2/11/202623.27 USD
2/10/202621.48 USD
2/9/202622.48 USD
2/6/202621.80 USD
2/5/202621.01 USD
2/4/202620.66 USD
2/3/202619.72 USD
2/2/202618.15 USD
1/30/202618.37 USD
1/29/202620.88 USD
1/28/202621.47 USD
1/27/202620.07 USD
1/26/202619.32 USD
1/23/202620.09 USD
1/22/202620.40 USD
1/21/202619.59 USD
1/20/202620.88 USD
1/16/202620.16 USD
1/15/202619.93 USD
1/14/202622.56 USD
1/13/202621.57 USD
1/12/202619.78 USD
1/9/202616.08 USD
1/8/202616.41 USD
1/7/202616.51 USD
1/6/202615.20 USD
1/5/202616.61 USD
1/2/202616.61 USD
12/31/202517.48 USD
12/30/202517.61 USD
12/29/202518.80 USD
12/26/202520.46 USD
12/24/202520.78 USD
12/23/202520.61 USD
12/22/202520.38 USD
12/19/202517.40 USD
12/18/202516.88 USD
12/17/202517.24 USD
12/16/202517.76 USD
12/15/202515.69 USD
12/12/202519.54 USD
12/11/202519.36 USD
12/10/202518.82 USD
12/9/202518.38 USD
12/8/202518.95 USD
12/5/202518.96 USD
12/4/202518.35 USD
12/3/202517.65 USD
12/2/202516.61 USD
12/1/202517.85 USD
11/28/202518.69 USD
11/26/202519.51 USD
11/25/202519.19 USD
11/24/202518.42 USD
11/21/202517.24 USD
11/20/202516.77 USD
11/19/202517.89 USD
11/18/202517.43 USD
11/17/202517.27 USD
11/14/202516.85 USD
11/13/202517.17 USD
11/12/202517.24 USD
11/11/202516.95 USD
11/10/202515.63 USD
11/7/202516.18 USD
11/6/202515.63 USD
11/5/202514.70 USD
11/4/202514.42 USD
11/3/202515.08 USD
10/31/202515.05 USD
10/30/202514.39 USD
10/29/202513.49 USD
10/28/202514.53 USD
10/27/202515.31 USD
10/24/202511.50 USD
10/23/202512.04 USD
10/22/202511.73 USD
10/21/202512.53 USD
10/20/202512.59 USD
10/17/202511.53 USD
10/16/202511.66 USD
10/15/202512.99 USD
10/14/202512.45 USD
10/13/202512.78 USD
10/10/202512.80 USD
10/9/202513.37 USD
10/8/202512.47 USD
10/7/202510.04 USD
10/6/202511.09 USD
10/3/202510.48 USD
10/2/202510.09 USD
10/1/202510.65 USD
9/30/202510.69 USD
9/29/20259.90 USD
9/26/20259.67 USD
9/25/20258.96 USD
9/24/20259.76 USD
9/23/20259.13 USD
9/22/20259.12 USD
9/19/20259.12 USD
9/18/20259.37 USD
9/17/20259.18 USD
9/16/20258.78 USD
9/15/202510.57 USD
9/12/20259.74 USD
9/11/20259.71 USD
9/10/20259.53 USD
9/9/202510.51 USD
9/8/202510.36 USD
9/5/20259.87 USD
9/4/20258.18 USD
9/3/20258.25 USD
9/2/20258.43 USD
8/29/20257.70 USD
8/28/20257.83 USD
8/27/20258.05 USD
8/26/20258.18 USD
8/25/20257.97 USD
8/22/20258.23 USD
8/21/20258.15 USD
8/20/20257.86 USD
Access this data via the Eulerpool API
Get Free API Key

Zenas Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
50.00 M USD
-37.15 M USD
-37.12 M USD
Jan 1, 2024
5.00 M USD
-163.89 M USD
-156.99 M USD
Jan 1, 2025
10.00 M USD
-211.39 M USD
-377.74 M USD
Jan 1, 2026 (e)
36.26 M USD
-11.66 M USD
-230.56 M USD
Jan 1, 2027 (e)
63.75 M USD
-24.40 M USD
-121.59 M USD
Jan 1, 2028 (e)
146.89 M USD
-56.66 M USD
-222.62 M USD
Jan 1, 2029 (e)
308.52 M USD
-119.01 M USD
-140.37 M USD
Jan 1, 2030 (e)
509.91 M USD
-196.69 M USD
-39.05 M USD

Zenas Biopharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 20, 2026, 3:09 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20222023202420252026e2027e2028e2029e2030e
–50.005.0010.0036.0063.00146.00308.00509.00
––-90.00100.00260.0075.00131.75110.9665.26
–100.00-2,680.00100.00100.00100.00100.00100.00100.00
-61.0050.00-134.0010.0036.0063.00146.00308.00509.00
-76.00-37.00-163.00-211.00-11.00-24.00-56.00-119.00-196.00
–-74.00-3,260.00-2,110.00-30.56-38.10-38.36-38.64-38.51
-119.00-37.00-156.00-377.00-230.00-121.00-222.00-140.00-39.00
–-68.91321.62141.67-38.99-47.3983.47-36.94-72.14
38.3238.3241.7946.4946.4946.4946.4946.4946.49
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Zenas Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zenas Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zenas Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Zenas Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zenas Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Zenas Biopharma stock margins

The Zenas Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zenas Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zenas Biopharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
-74.29 %
-74.25 %
Jan 1, 2024
-2,682.78 %
-3,277.76 %
-3,139.76 %
Jan 1, 2025
100.00 %
-2,113.85 %
-3,777.37 %
Jan 1, 2026 (e)
100.00 %
-32.14 %
-635.84 %
Jan 1, 2027 (e)
100.00 %
-38.28 %
-190.72 %
Jan 1, 2028 (e)
100.00 %
-38.57 %
-151.55 %

Zenas Biopharma Stock Revenue, EBIT, Earnings per Share

The Zenas Biopharma earnings per share therefore indicates how much revenue Zenas Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2022
0.00 USD
-1.99 USD
-3.11 USD
Jan 1, 2023
1.30 USD
-0.97 USD
-0.97 USD
Jan 1, 2024
0.12 USD
-3.92 USD
-3.76 USD
Jan 1, 2025
0.22 USD
-4.55 USD
-8.12 USD
Jan 1, 2026 (e)
0.68 USD
-0.25 USD
-4.30 USD
Jan 1, 2027 (e)
1.19 USD
-0.52 USD
-2.27 USD
Jan 1, 2028 (e)
2.74 USD
-1.22 USD
-4.15 USD

Zenas Biopharma business model & stock analysis

Zenas Biopharma Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Zenas Biopharma Employees
Details
Date
Zenas Biopharma Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Zenas Biopharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Zenas Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

Zenas Biopharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Zenas Biopharma shares outstanding

The number of shares of Zenas Biopharma was 46.49 M in 2025. This indicates how many shares Zenas Biopharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2022
38.32 M Stocks
Jan 1, 2023
38.32 M Stocks
Jan 1, 2024
41.79 M Stocks
Jan 1, 2025
46.49 M Stocks
Jan 1, 2026 (e)
46.49 M Stocks
Jan 1, 2027 (e)
46.49 M Stocks
Jan 1, 2028 (e)
46.49 M Stocks

Current Zenas Biopharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (12)
Hold
14.29 % (2)
Sell
0.00 % (0)
12M Price Target
45.39
Last Price
31.21
Currency
USD
12M Return Potential
45.43 %
LTM Return
0 %

Zenas Biopharma Analyst Rating Actions

DateFirmActionRatingReliability
8/14/2026
Wedbush
Wedbush
MaintainedOutperform55
8/14/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight46
8/14/2026
Guggenheim
Guggenheim
MaintainedBuy30
5/15/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/14/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight46
3/17/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight46
3/17/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/17/2026
Guggenheim
Guggenheim
MaintainedBuy30
3/17/2026
Citigroup
Citigroup
MaintainedBuy41
2/10/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Zenas Biopharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/18/2026-1.15USD-19.13 MUSD-2026 Q2
5/14/2026-1.62USD-0.00USD-2026 Q1
3/9/2026-1.05USD-39.10 MUSD-2025 Q4

EESG©

Eulerpool ESG Scorecard© for the Zenas Biopharma stock

28/100
26
Environment
35
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Zenas Biopharma shareholder structure

% Name
16.91878%
FMR LLC
FMR LLC
9.38497%
SR ONE CAPITAL MANAGEMENT, LP
SR ONE CAPITAL MANAGEMENT, LP
7.49482%
NEA MANAGEMENT COMPANY, LLC
NEA MANAGEMENT COMPANY, LLC
7.30097%
ENAVATE SCIENCES GP, LLC
ENAVATE SCIENCES GP, LLC
5.82532%
FEDERATED HERMES, INC.
FEDERATED HERMES, INC.
4.74747%
POLAR CAPITAL HOLDINGS PLC
POLAR CAPITAL HOLDINGS PLC
...

Zenas Biopharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
23.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
14.30%
FMR LLC
FMR LLC
SEC ↗
9.40%
InnoCare Pharma Inc.
InnoCare Pharma Inc.
SEC ↗
7.70%
SR One Capital Management, LLC
SR One Capital Management, LLC
SEC ↗
7.70%
Simeon George
Simeon George
SEC ↗
7.40%
Xencor, Inc.
Xencor, Inc.
SEC ↗
7.30%
Zebra Aggregator, LP
Zebra Aggregator, LP
SEC ↗
7.30%
Enavate Sciences GP, LLC
Enavate Sciences GP, LLC
SEC ↗
6.60%
Scott D. Sandell
Scott D. Sandell
SEC ↗
6.60%
Rick Yang
Rick Yang
SEC ↗
6.60%
Paul E. Walker
Paul E. Walker
SEC ↗

Zenas Biopharma Executives and Management Board

13 members · avg. age 57 · 38 % women

LM

Mr. Leon Moulder (67)

Founder, Chairman of the Board of Director, Chief Executive Officer · since 2020

20.00 M USD

Management

JF

Mr. Joseph Farmer (53)

President, Chief Operating Officer

6.00 M USD
OO

Mr. Orlando Oliveira (49)

Chief Commercial Officer

5.89 M USD
JF

Ms. Jennifer Fox (54)

Chief Business Officer, Chief Financial Officer

4.74 M USD
HL

Dr. Haley Laken

Chief Scientific Officer

–
LM

Dr. Lisa von Moltke (66)

Head of Research and Development, Chief Medical Officer

–

Board of Directors

PA

Ms. Patricia Allen (63)

Independent Director

564,412.00 USD
JO

Dr. John Orloff (67)

Independent Director

511,501.00 USD
JB

Mr. James Boylan (58)

Independent Director

494,981.00 USD
PE

Mr. Patrick Enright (63)

Independent Director

494,981.00 USD
JN

Mr. Jake Nunn (55)

Independent Director

493,668.00 USD
TK

Mr. Tomas Kiselak (38)

Independent Director

492,501.00 USD

Frequently asked questions about Zenas Biopharma

Analysts currently set an average price target of 41.57 USD for the Zenas Biopharma stock (median: 45.39 USD), implying +33.2 % versus the latest price. The consensus is based on 14 analyst ratings.

Zenas Biopharma Analyst Price Targets 2026

14 analysts currently rate the Zenas Biopharma stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Zenas Biopharma to generate revenue of 36.26 M USD and earnings per share of -4.96 USD.

Zenas Biopharma Analyst Price Targets 2026

Converted at the current exchange rate, the Zenas Biopharma share trades at 25.33 EUR (29.51 USD).

No history available for Zenas Biopharma.

The expected revenue of Zenas Biopharma is 36.26 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Zenas Biopharma is -230.56 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Zenas Biopharma is currently -5.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Zenas Biopharma stock.

The price-to-sales ratio (P/S) of Zenas Biopharma is currently 37.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Zenas Biopharma stock.

The Eulerpool Quality Score for Zenas Biopharma is 3/10.

The ISIN of Zenas Biopharma is US98937L1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Zenas Biopharma is ZBIO. The ticker symbol is used to trade Zenas Biopharma shares on the stock exchange.

Zenas Biopharma paid dividends every year for the past 0 years.

Zenas Biopharma is assigned to the 'Health' sector.

The dividends of Zenas Biopharma are distributed in USD.

All fundamentals and in-depth analysis of Zenas Biopharma

Our stock analysis for Zenas Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zenas Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Zenas Biopharma Stock
Zenas Biopharma Revenue→
Zenas Biopharma Stock
Zenas Biopharma Net Income→
Zenas Biopharma Stock
Zenas Biopharma P/E→
Zenas Biopharma Stock
Zenas Biopharma P/S→
Zenas Biopharma Stock
Zenas Biopharma EBIT→
Zenas Biopharma Stock
Zenas Biopharma Dividend→
Zenas Biopharma Stock
Zenas Biopharma Directors Dealings→
Zenas Biopharma Stock
Zenas Biopharma Stocks→
Zenas Biopharma Stock
Zenas Biopharma Market capitalization→
Zenas Biopharma Stock
Zenas Biopharma Debt→
Zenas Biopharma Stock
Zenas Biopharma Liabilities→
Zenas Biopharma Stock
Zenas Biopharma Equity→
Zenas Biopharma Stock
Zenas Biopharma AAQS→
Zenas Biopharma Stock
Zenas Biopharma Employees→
Zenas Biopharma Stock
Zenas Biopharma ROE→
Zenas Biopharma Stock
Zenas Biopharma ROA→
Zenas Biopharma Stock
Zenas Biopharma ROCE→
Zenas Biopharma Stock
Zenas Biopharma News→
Zenas Biopharma Stock
Zenas Biopharma Analyst Price Targets→

Health Stocks

Zenith HealthcareZelluna AZenotech LaboratoriesZelira TherapeuticsZentalis PharmaceuticalsZealand Pharma A/SZentekZai LabZEO ScientifiXYuyu PharmaZeria Pharmaceutical CoYunnan Energy International CoAll Stocks A–Z →